Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models
Background: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells. Methods: We investigated the effects of...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2017-09-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | http://www.endocrineconnections.com/content/6/7/469.full |
| _version_ | 1811228755691044864 |
|---|---|
| author | Joanna Klubo-Gwiezdzinska John Costello Jr Kirk Jensen Aneeta Patel Rok Tkavc Douglas Van Nostrand Kenneth D Burman Leonard Wartofsky Vasyl Vasko |
| author_facet | Joanna Klubo-Gwiezdzinska John Costello Jr Kirk Jensen Aneeta Patel Rok Tkavc Douglas Van Nostrand Kenneth D Burman Leonard Wartofsky Vasyl Vasko |
| author_sort | Joanna Klubo-Gwiezdzinska |
| collection | DOAJ |
| description | Background: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells.
Methods: We investigated the effects of the active form of amifostine (WR-1065) on the response of thyroid cancer cells to treatment with DNA-damaging agents. WR-1065 was examined in human thyroid cancer cell lines (FTC133, TPC1, BCPAP and C643) and embryonic fibroblast cells NIH3T3. DNA damage was induced by exposure to H2O2 (0.1 mM), by treatment with the radiomimetic neocarzinostatin (NCS 250 ng/mL) and by γ-radiation (6 Gy). DNA damage, cell viability and apoptosis were examined.
Results: We demonstrated the selective action of WR-1065 (0.1 mM), which prevented oxidative stress–induced DNA damage in fibroblasts, but did not protect thyroid cancer cells from DNA damage and apoptosis documented by caspase-3 and PARP cleavage after exposure to H2O2, NCS and γ-radiation. Prolonged exposure to WR-1065 (0.1 mM for 24 h) was toxic for thyroid cancer cells; this treatment decreased the number of viable cells by 8% in C643 cells, 47% in TPC cells, 92% in BCPAP cells and 82% in FTC 133 cells. The cytotoxic effects of WR-1065 were not associated with induction of apoptosis.
Conclusions: Our data show that amifostine has no protective effect on thyroid cancer cells against DNA-damaging agents in vitro and suggest that amifostine will not attenuate the efficacy of radioiodine treatment in patients with thyroid cancer. |
| first_indexed | 2024-04-12T10:01:47Z |
| format | Article |
| id | doaj.art-19b9866d1f2a490a850174fada7c7fb8 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 2049-3614 |
| language | English |
| last_indexed | 2024-04-12T10:01:47Z |
| publishDate | 2017-09-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-19b9866d1f2a490a850174fada7c7fb82022-12-22T03:37:32ZengBioscientificaEndocrine Connections2049-36142049-36142017-09-016746947810.1530/EC-17-0138Amifostine does not protect thyroid cancer cells in DNA damaging in vitro modelsJoanna Klubo-Gwiezdzinska0John Costello Jr1Kirk Jensen2Aneeta Patel3Rok Tkavc4Douglas Van Nostrand5Kenneth D Burman6Leonard Wartofsky7Vasyl Vasko8National Institute of Health, NIDDK, Office 10 Center Drive, Bethesda, Maryland, USA; Division of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USADepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USADepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USADepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USADepartment of Pathology, Uniformed Services University of the Health Sciences, Henry Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USADivision of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USADivision of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USADivision of Endocrinology, Department of Medicine, Medstar Washington Hospital Center, Washington Hospital Center, Northwest, Washington, District of Columbia, USADepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USABackground: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells. Methods: We investigated the effects of the active form of amifostine (WR-1065) on the response of thyroid cancer cells to treatment with DNA-damaging agents. WR-1065 was examined in human thyroid cancer cell lines (FTC133, TPC1, BCPAP and C643) and embryonic fibroblast cells NIH3T3. DNA damage was induced by exposure to H2O2 (0.1 mM), by treatment with the radiomimetic neocarzinostatin (NCS 250 ng/mL) and by γ-radiation (6 Gy). DNA damage, cell viability and apoptosis were examined. Results: We demonstrated the selective action of WR-1065 (0.1 mM), which prevented oxidative stress–induced DNA damage in fibroblasts, but did not protect thyroid cancer cells from DNA damage and apoptosis documented by caspase-3 and PARP cleavage after exposure to H2O2, NCS and γ-radiation. Prolonged exposure to WR-1065 (0.1 mM for 24 h) was toxic for thyroid cancer cells; this treatment decreased the number of viable cells by 8% in C643 cells, 47% in TPC cells, 92% in BCPAP cells and 82% in FTC 133 cells. The cytotoxic effects of WR-1065 were not associated with induction of apoptosis. Conclusions: Our data show that amifostine has no protective effect on thyroid cancer cells against DNA-damaging agents in vitro and suggest that amifostine will not attenuate the efficacy of radioiodine treatment in patients with thyroid cancer.http://www.endocrineconnections.com/content/6/7/469.fullthyroid canceramifostineradiationDNA damage |
| spellingShingle | Joanna Klubo-Gwiezdzinska John Costello Jr Kirk Jensen Aneeta Patel Rok Tkavc Douglas Van Nostrand Kenneth D Burman Leonard Wartofsky Vasyl Vasko Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models Endocrine Connections thyroid cancer amifostine radiation DNA damage |
| title | Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models |
| title_full | Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models |
| title_fullStr | Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models |
| title_full_unstemmed | Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models |
| title_short | Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models |
| title_sort | amifostine does not protect thyroid cancer cells in dna damaging in vitro models |
| topic | thyroid cancer amifostine radiation DNA damage |
| url | http://www.endocrineconnections.com/content/6/7/469.full |
| work_keys_str_mv | AT joannaklubogwiezdzinska amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT johncostellojr amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT kirkjensen amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT aneetapatel amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT roktkavc amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT douglasvannostrand amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT kennethdburman amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT leonardwartofsky amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels AT vasylvasko amifostinedoesnotprotectthyroidcancercellsindnadamaginginvitromodels |